<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963846</url>
  </required_header>
  <id_info>
    <org_study_id>Biomedisyn 200901</org_study_id>
    <secondary_id>3R41MH083436-01A1S1</secondary_id>
    <nct_id>NCT00963846</nct_id>
  </id_info>
  <brief_title>Huperzine for Cognitive and Functional Impairment in Schizophrenia</brief_title>
  <official_title>Huperzine for Cognitive and Functional Impairment in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomedisyn Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomedisyn Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Huperzine is a natural plant product with procognitive properties in patients with&#xD;
      Alzheimer's disease. Cognitive difficulties hamper functioning in schizophrenia as well. The&#xD;
      present study will investigate whether huperzine improves cognition and functioning in&#xD;
      patients with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MATRICS battery</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPSA</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>huperzine 0.2 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>huperzine 0.4 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>huperzine 0.8 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching pill placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>huperzine 0.2 mg BID</intervention_name>
    <description>huperzine rising doses up to 0.2 mg BID</description>
    <arm_group_label>huperzine 0.2 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>huperzine 0.4 mg BID</intervention_name>
    <description>huperzine rising doses up to 0.4 mg BID</description>
    <arm_group_label>huperzine 0.4 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>huperzine 0.8 mg BID</intervention_name>
    <description>huperzine rising doses up to 0.8 mg BID</description>
    <arm_group_label>huperzine 0.8 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Psychiatric diagnosis of schizophrenia according to SCID-IV.&#xD;
&#xD;
          2. Currently treated with an antipsychotic medication.&#xD;
&#xD;
          3. Has tolerated current antipsychotic treatment adequately.&#xD;
&#xD;
          4. Has received an adequate trial of antipsychotic (a least 3 months of at least 300 mg/d&#xD;
             CPZ equivalent).&#xD;
&#xD;
          5. Has been receiving current psychotropic medication (s) for at least 8 weeks.&#xD;
&#xD;
          6. Has been receiving current doses of psychotropic medication (s) for at least 4 weeks.&#xD;
&#xD;
          7. Has been clinically stable for at least 12 weeks.&#xD;
&#xD;
          8. No more than moderate severity (4 on the 1-7 scale) on any PANSS positive item.&#xD;
&#xD;
          9. No more than 15 on the total of PANSS negative symptom items.&#xD;
&#xD;
         10. Simpson-Angus Scale total score &lt;7.&#xD;
&#xD;
         11. Calgary Depression Scale for Schizophrenia total score &lt;11.&#xD;
&#xD;
         12. Submaximal performance on at least one of the following MATRICS components&#xD;
             (letter-number span &lt;20 OR HVLT total &lt;31 OR CPT d-prime &lt; 3.47).&#xD;
&#xD;
         13. Score &gt; 1 SD below age-, gender-, and education-adjusted normal control mean on&#xD;
             MATRICS composite&#xD;
&#xD;
         14. Good general health with no additional diseases expected to interfere with the&#xD;
             studies.&#xD;
&#xD;
         15. Fluent in English.&#xD;
&#xD;
         16. Age 18-55.&#xD;
&#xD;
         17. Adequate visual and auditory acuity to allow neuropsychological testing.&#xD;
&#xD;
         18. Able to ingest oral medication.&#xD;
&#xD;
         19. Not pregnant or lactating (women of childbearing potential must use a medically&#xD;
             accepted method of birth control).&#xD;
&#xD;
         20. Onset of schizophrenia prior to age 45.&#xD;
&#xD;
         21. Available informant knowledgeable about subject's current functioning.&#xD;
&#xD;
         22. Informed consent obtained from the subject prior to entry into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Poor reading skills (raw score on MATRICS Wechsler Test of Adult Reading &lt; 6).&#xD;
&#xD;
          2. History of systemic cancer within 5 years.&#xD;
&#xD;
          3. Use of any investigational drugs within 30 days prior to the screening visit.&#xD;
&#xD;
          4. Use of cholinesterase inhibitors (galantamine, rivastigmine, donepezil, or tacrine)&#xD;
             within 4 weeks of screening.&#xD;
&#xD;
          5. Any clinically significant laboratory test abnormality on screening tests (hematology,&#xD;
             chemistry, urinalysis, EKG). Clinically significant LFT elevations will be defined as&#xD;
             &gt;2x the upper limit of normal.&#xD;
&#xD;
          6. Any significant neurologic disease including Alzheimer's disease, parkinson's disease,&#xD;
             stroke, huntington's disease, normal pressure hydrocephalus, brain tumor, progressive&#xD;
             supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history&#xD;
             of head injury with loss of consciousness for greater than one day within the past 5&#xD;
             years, or with residual deficits.&#xD;
&#xD;
          7. Use of antihypertensive agents with frequent CNS side effects (e.g. clonidine,&#xD;
             propranolol) within 4 weeks prior to the screening visit.&#xD;
&#xD;
          8. Use of medications known to alter drug absorption or metabolism (e.g. probenecid,&#xD;
             cimetidine, anti-fungal agents, erythromycin, rifampin, and anticonvulsants) within 4&#xD;
             weeks prior to the screening visit.&#xD;
&#xD;
          9. History of peptic ulcer disease within 2 years.&#xD;
&#xD;
         10. History of myocardial infarction, significant cardiovascular disease, or congestive&#xD;
             heart failure within 6 months, history of hepatic or renal insufficiency,&#xD;
             insulin-requiring diabetes or uncontrolled diabetes mellitus.&#xD;
&#xD;
         11. Clinically significant cardiac arrhythmia, resting pulse less than 50.&#xD;
&#xD;
         12. Present use or use in the 4 weeks prior to screening of anti-parkinsonian or&#xD;
             anticholinergic medications (e.g. Sinemet, amantadine, bromocriptine, pergolide,&#xD;
             selegiline, atropine, scopolamine, benztropine, trihexyphenidyl, hydroxyzine,&#xD;
             diphenhydramine).&#xD;
&#xD;
         13. Use of narcotic analgesics within 4 weeks prior to the screening visit.&#xD;
&#xD;
         14. History of alcohol or substance abuse or dependence within the past 2 years (DSM-IV&#xD;
             criteria).&#xD;
&#xD;
         15. Receiving CYP 1A2 inhibitors such as certain SSRIs (all excluded in #4) cimetidine,&#xD;
             methoxsalen, quinolones, furafylline, or moclobemide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott W Woods, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedisyn Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Biomedisyn Corporation</investigator_affiliation>
    <investigator_full_name>Scott Woods, MD</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>cognition</keyword>
  <keyword>functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huperzine A</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 8, 2016</submitted>
    <returned>October 27, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

